Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Oxaliplatin 49Fluorouracil 46Capecitabine 41Cisplatin 36Gemcitabine 29Leucovorin 27Bevacizumab 21Drug Therapy 20Paclitaxel 15Folfox protocol 15Radiotherapy 14Irinotecan 14apatinib 11Neoadjuvant Therapy 11Docetaxel 11sintilimab 9S 1 (combination) 9Sorafenib 8Nivolumab 8Trastuzumab 7Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 7lenvatinib 6atezolizumab 6XELOX 6Cetuximab 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6tislelizumab 5pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Drugs, Investigational × Gastrointestinal × Clear all
NCT05409417 2022-06-08

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Unknown
40 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡